Login to Your Account

Dosing Troubles Snag Treprostinil

Bad News, Good News for United's Oral PAH Program

By Jennifer Boggs

Tuesday, November 18, 2008
Despite United Therapeutics Corp.'s best efforts to put a positive spin on its oral pulmonary arterial hypertension (PAH) program by highlighting a recent in-licensing deal for Eli Lilly and Co.'s late-stage tadalafil, the company's shares sank 35 percent on a Phase III miss with its own oral PAH drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription